Form 4 Filing: Lin Patrick Buys $4,065.74 of $PCSA
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Lin Patrick, holds the title of Chief Business - Strategy Off at Processa Pharmaceuticals, Inc..
On 2026-05-29, the insider transacted 1,582 shares.The shares were transacted at a weighted average price of $2.57 per share, resulting in a total market-relevant value of $4,065.74.
**Transaction:** buy of 1,582 shares by Lin Patrick (Chief Business - Strategy Off). **Strategic Implications (Investor Edge):** This open market purchase by a C-suite executive, albeit not the CEO or CFO, signals insider confidence at a relatively low price point. The modest size suggests a personal conviction buy rather than a market-moving signal, but it is a positive indicator for retail investors monitoring insider activity. **Key Takeaways:** - Open market purchase by Chief Business Strategy Officer indicates insider bullishness. - Transaction increased insider's holdings by 20.8%, showing meaningful commitment. - Purchase at $2.57 per share may reflect undervaluation or upcoming catalysts.
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.